P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

NCT05905055 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Complicated Urinary Tract Infection
Acute Pyelonephritis
Hospital-acquired Bacterial Pneumonia
Ventilator-associated Bacterial Pneumonia
Complicated Intra-abdominal Infection

Interventions

DRUG: co-administration of cefepime and nacubactam
DRUG: co-administration of aztreonam and nacubactam
DRUG: BAT

Sponsor

Meiji Seika Pharma Co., Ltd.